Dyslipidemia: Causes, Symptoms and Treatment

Wen Chen, Lei Xu, Yonggui YuanInternational Journal of Trend in Scientific Research and Development 2021

Abstract

Dyslipidemia, characterized by abnormal levels of lipids in the blood, remains a primary risk factor for coronary heart disease (CHD). This review synthesizes current clinical guidelines and pharmacological research to detail the genetic and acquired origins of the condition. It establishes diagnostic thresholds for both adults and children and evaluates the efficacy of modern drug therapies, such as statins and nicotinic acid, in managing cardiovascular risk.

Introduction

Coronary Heart Disease (CHD) continues to be a leading cause of global mortality. While advancements in medical care have reduced death rates in certain regions, dyslipidemia—the presence of unhealthy lipid levels—remains the most significant known risk factor in the development of atherosclerosis and subsequent CHD. Managing lipid levels involves a complex balance between high-density lipoprotein (HDL), often termed "good" cholesterol, and "bad" cholesterol, which includes low-density lipoprotein (LDL) and triglycerides. This paper consolidates current clinical benchmarks and pharmacological options to provide a comprehensive reference for lipid management.

Classification and Diagnosis

Dyslipidemia is categorized into two main types: primary and secondary. Primary dyslipidemia is genetic or inherited, while secondary dyslipidemia is acquired through lifestyle factors such as obesity or conditions like diabetes.

To establish baseline "acceptable" lipid levels, clinicians rely on established benchmarks, such as the 2018 Journal of the American College of Cardiology (JACC) guidelines. These guidelines provide specific milligram per deciliter (mg/dL) thresholds for Total Cholesterol, HDL, LDL, and Triglycerides across different age groups and health profiles.

Table 1: Adult Lipid Level Thresholds (mg/dL)

Key Insights in Lipid Management

A critical distinction exists between hyperlipidemia and dyslipidemia. While hyperlipidemia refers specifically to elevated LDL levels, dyslipidemia is a broader term encompassing any unhealthy lipid profile, including insufficient levels of HDL. HDL plays a protective role by actively removing LDL from the bloodstream, thereby preventing the formation of arterial plaques.

Furthermore, pediatric standards are increasingly emphasized. For children (ages 0–19), "good" total cholesterol is defined as <170 mg/dL, which is significantly lower than the <200 mg/dL threshold for adults. This highlights the necessity for early monitoring, particularly in families with a history of genetic predisposition to heart disease. Beyond simple lipid reduction, some modern therapies offer pleiotropic benefits, such as inhibiting vascular inflammation and reducing the oxygenation of LDL-C, which are vital steps in preventing strokes and myocardial infarctions.

Pharmacological Landscape

While lifestyle modifications are foundational, they often only achieve a 10% to 20% reduction in cholesterol. Consequently, pharmacological intervention is frequently required for high-risk patients. The paper summarizes the efficacy of several key drug classes:

  • Statins (HMG-CoA reductase inhibitors): Recognized as the gold standard for LDL reduction, statins can lower LDL by 20% to 60% and total cholesterol by 15% to 30%.
  • Nicotinic Acid (Niacin): This is highly effective for increasing HDL levels (by 15% to 35%) and reducing triglycerides (by 20% to 50%).
  • Fibric Acid Analogs: These agents boost HDL by 14% to 20% while reducing total cholesterol and LDL.
  • Bile Acid Resins: These can reduce total cholesterol by approximately 20%, though their effect on triglycerides is typically neutral or slightly escalatory.

Challenges and Future Directions

Despite the efficacy of these treatments, significant hurdles remain. Many pharmacological options carry substantial side effects, such as the "flushing" and hepatotoxicity associated with Niacin or the myalgia (muscle pain) often reported by patients on statins.

Future research is shifting toward human genetics as a primary frontier. Current efforts are focused on targeting Triglyceride-Rich Lipoproteins (TRL) to further mitigate cardiovascular risk beyond what is achievable with current LDL-focused therapies.

Summary updated

BibTeX
@article{chen2021dyslipidemia,
  author = {Wen Chen and Lei Xu and Yonggui Yuan},
  title = {{Dyslipidemia: Causes, Symptoms and Treatment}},
  journal = {International Journal of Trend in Scientific Research and Development},
  year = {2021},
}
Figure